# Holoclara

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/holoclara

- Industry: Pharmaceuticals
- Headquarters: Los Angeles, US
- Website: www.holoclara.com
- Total disclosed funding: $16M
- Latest round: Series A (Jun 27, 2024)
- Investors on record: 6

## About

Holoclara, Inc. is a US-based company focused on developing innovative therapeutic solutions that leverage parasitic worms to treat debilitating diseases, aiming to provide alternative relief for chronic health conditions.Founded in 2017 and headquartered in Los Angeles, California, Holoclara, Inc. specializes in therapeutic solutions utilizing parasitic worms to address chronic health challenges. The company has successfully completed a total of 3 funding deals, with the most recent occurring on June 27, 2024. In this Series A funding round, Holoclara raised USD 16.000 mn led by BOLD Capital Partners and included participation from investors such as Endurance28, Freeflow Ventures, and Horizons Ventures. Andrea Choe serves as both the founder and CEO of the company, contributing her expertise in healthcare innovation.Holoclara primarily focuses on innovative therapeutic solutions aimed at alleviating debilitating diseases through the unique application of parasitic worms. Their core product offerings leverage the biological properties of these organisms to promote health and potentially treat a range of chronic conditions. The end users of Holoclara's offerings are individuals suffering from various diseases that traditional treatments have not effectively addressed. Their products are tailored to provide relief by harnessing the immunomodulatory effects of parasitic worms, thus addressing critical health challenges faced by millions globally. Holoclara's solutions target markets in North America, Europe, and parts of Asia, where there is a significant demand for alternative therapeutic options for chronic health issues.Holoclara generates revenue through direct-to-consumer sales and partnerships with healthcare providers who incorporate their therapeutic solutions into treatment regimens. The company operates on a subscription-based model, providing patients access to their products over specified periods, thereby ensuring a steady flow of income. Additionally, Holoclara collaborates with healthcare institutions to offer their therapies as part of integrated treatment programs. While specific pricing plans for their flagship products are proprietary, the company’s revenue structure is designed to support both individual consumers and institutional partners, enhancing the accessibility of their innovative solutions in the healthcare market.In June 2024, Holoclara, Inc. raised USD 16.000 mn in Series A funding, which will be utilized to support its clinical development initiatives. The company is working on launching new therapeutic products aimed at expanding its portfolio and is targeting further market penetration in regions such as Europe and Asia by the end of 2025. The recent funding will facilitate the advancement of these products through clinical trials, thereby positioning Holoclara for enhanced market presence and operational growth.

## Funding rounds

- Series A, Jun 27, 2024, $16M — Horizons Ventures, BOLD Capital Partners, Freeflow Ventures, Tarrasque, Endurance28
- Seed, May 9, 2017 — Kairos Ventures

## Investors

- Kairos Ventures (https://capitalatlas.ai/funds/kairos-ventures) — Seed
- Horizons Ventures — Series A
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Series A
- Freeflow Ventures (https://capitalatlas.ai/funds/freeflow-ventures) — Series A
- Tarrasque — Series A
- Endurance28 (https://capitalatlas.ai/funds/endurance28) — Series A